Genetics of Smoking
Dr. Sean David’s research encompasses a collaborative, transdisciplinary initiative to translate molecular insights to genomically tailored and patient-centered personalized medicine and science-based policy to improve population health. Investigations are focused on the integration of three translational streams of investigation. The first stream triangulates genome-wide association studies with preclinical research using functional neuroimaging and other modalities aimed at elucidating biobehavioural mechanisms nicotine dependence and smoking cessation. The second stream investigates moderating effects of genotype on health-related behavior and drug response (particularly in smoking cessation treatment) in multiple ancestral populations. The third stream investigates clinical implementation and health care policy research. Projects range from studying the efficacy of genomically tailored drug and behavioral therapies, and clinical and translational research (e.g., systematic review/meta-analyses, genome-wide and exome-wide meta-analyses, publication bias and data fidelity science, cost-effectiveness analyses, knowledgeable healthcare delivery systems, educating the primary care workforce, & tobacco regulatory science). His current projects include the following:
Behaviorally-Enhanced Counseling on Nicotine Dependence (BEACON) Trial (completed): The BEACON Trial, funded by the National Institute on Drug Abuse (NIDA)/National Institutes of Health (NIH), is and developed and initiated the, in progress, The BEACON Trial was the first U.S. prospective, genetically tailored feasibility trial of pharmacotherapy for smoking cessation, which is studying the feasibility of implementing personalized medicine for smoking cessation in large health care organization (Group Health Cooperative). More details about the BEACON Trial and this topic can be found in this publication or by Clicking Here»
Medical Students helping patients Quit Tobacco (MSQuit) Trial (completed): Dr. David is the Stanford University site PI for the MSQuit Study, (PI: Judith Ockene, Ph.D., University of Massachusetts), which is a randomized trial of multimodal medical education for smoking cessation in 10 U.S. medical schools funded by the National Cancer Institute. In the MS-Quit Trial, Stanford students have been participating in surveys and clinical performance examinations and combined with students from other participating schools, more than 1,000 medical students are participating in MSQuit. Stanford medical students will be followed for the next three years in the largest study of its kind to date. More details about the MSQuit Trial are available here » Extended Treatment for Smoking Cessation: Dr. David is co-investigator and study physician for this randomized clinical trial of extended cognitive behavioral therapy, combined with pharmacotherapy, for smoking cessation and relapse prevention. This trial is funded by the National Cancer Institute/NIH (PI: Sean David Stanford University). More details about the Extended Treatment Trial are Available Here», or in these pulications, PMID:23623894, PMID:24486635. In addition, he co-led the Study of Tobacco use in Minority Populations (STOMP) Genetics Consortium, which was the first genome-wide meta-analysis of smoking behaviors in African Americans and which identified a genome-wide significant polymorphism associated with smoking quantity and drug response for smoking cessation in African Americans, described in these publications: PMID:22822964, PMID:23733007.
Extended Treatment for Smoking Cessation (ongoing): Dr. David is co-investigator and study physician for this randomized clinical trial of extended cognitive behavioral therapy, combined with pharmacotherapy, for smoking cessation and relapse prevention. This trial is funded by the National Cancer Institute/NIH (PI: Sean David Stanford University). More details about the Extended Treatment Trial are Available Here».
Additional projects are focused on reducing publication bias and increasing the fidelity of science and translating clinical and translational research into evidence-based clinical applications and policy through his work as a James C. Puffer, MD/American Board of Family Medicine/Institute of Medicine Anniversary Fellow (2011-2013), current participation in the Institute of Medicine Roundtable on Translating Genomic-Based Research for Health Knowledgeable Healthcare System Working Group, Stanford’s Pharmacogenomics Knowledgebase (PharmGKB), the Strategic Dialogue on Harm Reduction II, the Scientific Advisory Committee of the University of California Office of the President Tobacco Disease-Related Research Program (TRDRP) and the Board of US BMJ Fellows. Representative collaborative papers include: PMID:23936149, PMID:24656991, PMID:21935354, PMID:24618965.